1. A pharmaceutical composition comprising one or more components selected from the group consisting of: (i) a tumor associated antigen or part thereof, (ii) a nucleic acid encoding a tumor associated antigen or a part thereof, (iii) an antibody that binds to a tumor associated antigen, (iv) an antisense nucleic acid specifically hybridizing to a nucleic acid encoding a tumor-associated antigen, (v) siRNA directed against a nucleic acid encoding a tumor-associated antigen, (vi) a cell a host expressing a tumor-associated antigen or part thereof, and (vii) an isolated complex between a tumor-associated antigen or part thereof and an MHC molecule, wherein said part contains at least 6 consecutive amino acids of the tumor-associated antigen, wherein the tumor-associated antigen has a sequence that is encoded a nucleic acid selected from the group consisting of: (a) a nucleic acid containing the nucleotide sequence of SEQ ID NO: 1, (b) a nucleic acid hybridizing with a nucleic acid of (a) under stringent conditions, (c) a nucleic acid degenerate with respect to a nucleic acid of (a) or (b), and (d) a nucleic acid complementary to a nucleic acid of (a), (b ) or (c). 2. The pharmaceutical composition of claim 1, wherein the nucleic acid of (ii) is in an expression vector. The pharmaceutical composition of claim 1, wherein the host cell secretes a tumor-associated antigen or part thereof. The pharmaceutical composition of claim 1, wherein the host cell further expresses an MHC molecule,1. Фармацевтическая композиция, включающая один или несколько компонентов, выбранных из группы, состоящей из:(i) опухолеассоциированного антигена или его части,(ii) нуклеиновой кислоты, кодирующей опухолеассоциированный антиген или его часть,(iii) антитела, связывающегося с опухолеассоциированным антигеном,(iv) антисмысловой нуклеиновой кислоты, специфически гибридизующейся с нуклеиновой кислотой, кодирующей опухолеассоциированный антиген,(v) siRNA, направленной против нуклеиновой кислоты, к
